Aim: To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab.
Methods: This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events.
Results: There was no change in the mean logarithm of minimum angle of resolution (logMAR) BCVA at baseline and following treatment with IVZ therapy (p=0.978). The mean number of IVZ injections during 12 months was 5.9±3.3, and the mean number of antivascular endothelial growth factors (VEGFs) injections prior to switching to IVZ was 8.4±4.7. The mean treatment free interval was longer during IVZ therapy (114.4±67.1 days) compared with 76.3±54.6 days before IVZ therapy (p=0.03). Five (31.25%) eyes had visual gains of at least 0.1 logMAR, 3 (18.75%) eyes had stable BCVA (within 0.1 logMAR) and 8 (50%) eyes had BCVA decline of at least 0.1 logMAR. There was no significant difference in the mean CMT, RPED heights and presence of IRF and SRF at 12 months compared with baseline. No adverse events were noted.
Conclusion: IVZ increased the treatment free interval in non-responders but no significant change in visual and anatomic outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjophthalmol-2017-310318 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- - Mucormycosis is a severe fungal infection with high risks for individuals, especially those who are immunocompromised, leading to significant tissue damage and health complications
- - A case study showed successful treatment of pulmonary mucormycosis using isavuconazole (IVZ) in a patient who couldn't tolerate another antifungal, liposomal amphotericin B (L-AMB)
- - This case suggests that monitoring IVZ levels may be important for effective treatment, particularly in patients requiring renal therapy, indicating a need for further research on optimal dosing strategies.
Assessment of active translation in cumulus-enclosed and denuded oocytes during standard in vitro maturation and early embryo development.
Hum Reprod
August 2024
Laboratory of Biochemistry and Molecular Biology of Germ Cells, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic.
Study Question: Which actively translated maternal transcripts are differentially regulated between clinically relevant in vitro and in vivo maturation (IVM) conditions in mouse oocytes and zygotes?
Summary Answer: Our findings uncovered significant differences in the global transcriptome as well as alterations in the translation of specific transcripts encoding components of energy production, cell cycle regulation, and protein synthesis in oocytes and RNA metabolism in zygotes.
What Is Known Already: Properly regulated translation of stored maternal transcripts is a crucial factor for successful development of oocytes and early embryos, particularly due to the transcriptionally silent phase of meiosis.
Study Design, Size, Duration: This is a basic science study utilizing an ICR mouse model, best suited for studying in vivo maturation.
Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population.
Eye (Lond)
May 2022
Academic Ophthalmology, DCN, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Aim: To investigate the use of intravitreal ziv-aflibercept (IVZ) in Ghanaian patients with diabetic macular edema (DME).
Methods: A retrospective study of patients with DME, who had been treated with IVZ (1.25 mg/0.
Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
Int Ophthalmol
July 2021
Academic Ophthalmology, DCN, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Aim: To evaluate the efficacy of ziv-aflibercept in Ghanaian patients with macular edema (ME) secondary to retinal vein occlusion (RVO).
Methodology: In this retrospective study, the medical records of patients with ME secondary to RVO who had been treated with intravitreal ziv-aflibercept (IVZ) (1.25 mg/0.
Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza.
Ann Pharmacother
June 2021
West Virginia University, Morgantown, WV, USA.
Objective: To review the pharmacology, clinical trial data, and clinical implications for the intravenous formulation of zanamivir.
Data Sources: MEDLINE, PubMed, EMBASE, and Google Scholar were searched during November 2019 to July 2020. Search terms and were used.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!